News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MiniVax And University of Rochester Enter Into Option For Antibody Treatment Against Pneumocystis Pneumonia



1/9/2014 10:22:06 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW ORLEANS & ROCHESTER, N.Y.--(BUSINESS WIRE)--MiniVax, Inc. (New Orleans, LA) and the University of Rochester (Rochester, NY) announce that they have entered into an exclusive option agreement with agreed licensing terms to develop a monoclonal antibody for the treatment of Pneumocystis pneumonia (PCP). The antibody of interest is a product of research conducted at the University of Rochester. PCP is a life-threatening, fungal respiratory infection that affects patients with weakened immune systems such as those suffering from HIV/AIDS, receiving organ transplants, and undergoing chemotherapy.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   
Pneumonia

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES